ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
AN2 Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.37−0.01 (-0.30%)
Close on Oct 19, 2026
- Market cap
- $150.84M
- P/E (TTM)
- –
- Dividend yield
- –
AN2 Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | AN2 Therapeutics | Industry median |
|---|---|---|
| Market Cap | $127.17M | $166.30M |
| Enterprise Value | $48.78M | $88.19M |
| PB Ratio | 1.68 | 2.03 |
| P/TBV Ratio | 1.68 | 2.29 |
Income (trailing twelve months)
| Measure | AN2 Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$38.81M | -$21.40M |
| Net Income | -$36.24M | -$22.46M |
| EBITDA | -$38.81M | -$16.91M |
| EPS (Diluted) | -$1.07 | -$0.83 |
Returns
| Measure | AN2 Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -50.1% | -53.2% |
| Return on Assets (ROA) | -46.0% | -40.9% |
| Return on Invested Capital (ROIC) | -1772.3% | -32.4% |
| Return on Capital Employed (ROCE) | -51.0% | -38.1% |
Balance sheet
| Measure | AN2 Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $78.39M | $61.43M |
| Net Cash (Debt) | $78.39M | $15.35M |
| Net Cash Per Share | $2.08 | $0.66 |
| Equity (Book Value) | $75.92M | $49.09M |
| Book Value Per Share | $2.01 | $1.37 |
| Tangible Book Value | $75.92M | $23.52M |
| Working Capital | $74.41M | $76.81M |
Financial position
| Measure | AN2 Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 14.32 | 3.34 |
| Quick Ratio | 14.04 | 2.44 |
Cash flow (trailing twelve months)
| Measure | AN2 Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$30.68M | -$12.35M |
Efficiency
| Measure | AN2 Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.73M | -$703.34K |
| Employee Count | 21 | 74 |
Dividends and yields
| Measure | AN2 Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -28.5% | -23.3% |
Shares
| Measure | AN2 Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 37,736,200 | 58,127,000 |
| Shares Change (YoY) | 16.3% | 10.9% |
| Shares Change (QoQ) | 0.90% | 0.54% |
| Float | 30,113,400 | 49,136,700 |
| Shares Held by Insiders | 20.2% | 11.6% |
| Shares Held by Institutions | 65.1% | 59.4% |
Scores
| Measure | AN2 Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 8.34 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from AN2 Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.